Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation - Benito-Villalvilla, C; de la Rocha-Muñoz, A; López-Abente, J (Allergy, 2023)